Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses how the clinical trials, CHAARTED and STAMPEDE, have impacted his treatment for patients with metastatic hormone sensitive prostate cancer. He states that his patients who received chemotherapy from the study are doing remarkably well and are one step closer to eliminating the entire disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Metastatic Prostate Cancer Patients from CHAARTED and STAMPEDE Showed Major Signs of Improvement
